INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 3 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,514,981 | -18.7% | 67,479 | -1.2% | 0.00% | -20.0% |
| Q2 2023 | $4,324,566 | +14.9% | 68,297 | -1.8% | 0.01% | +25.0% |
| Q1 2023 | $3,765,104 | -34.0% | 69,531 | -35.5% | 0.00% | -42.9% |
| Q4 2022 | $5,709,010 | -58.5% | 107,880 | -63.5% | 0.01% | -56.2% |
| Q3 2022 | $13,745,000 | -78.8% | 295,395 | -74.0% | 0.02% | -78.4% |
| Q2 2022 | $64,777,000 | +13.8% | 1,134,850 | +21.7% | 0.07% | +29.8% |
| Q1 2022 | $56,901,000 | – | 932,322 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 675,000 | $26,203,000 | 7.44% |
| EcoR1 Capital, LLC | 244,950 | $9,509,000 | 3.75% |
| Redmile Group, LLC | 971,565 | $37,716,000 | 3.60% |
| Ghost Tree Capital, LLC | 120,000 | $4,658,000 | 1.34% |
| SENZAR ASSET MANAGEMENT, LLC | 144,624 | $5,614,304,000 | 1.22% |
| GREAT POINT PARTNERS LLC | 100,000 | $3,882,000 | 1.11% |
| BB BIOTECH AG | 700,000 | $27,174,000 | 1.07% |
| Rhenman & Partners Asset Management AB | 115,000 | $4,464,000 | 0.79% |
| Lisanti Capital Growth, LLC | 12,260 | $476,000 | 0.72% |
| Rock Springs Capital Management LP | 190,000 | $7,376,000 | 0.55% |